Enveric Biosciences (NASDAQ: ENVB) Reports 2025 Year-End Financial Results & Major Corporate Developments

Key Highlights and Potential Share Price Catalysts for Investors

Product Development Milestones

• EB-003: Groundbreaking Preclinical Results
  • Enveric’s lead candidate, EB-003, demonstrated statistically significant improvements in preclinical animal models of severe chronic depression, despair, and post-traumatic stress disorder (PTSD).
  • EB-003 is a non-hallucinogenic neuroplastogen, uniquely designed to promote neuroplasticity without hallucinogenic effects. It selectively targets both 5-HT_2A and 5-HT_1B receptors, aiming to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.
  • Recent independent academic research supports Enveric’s mechanistic approach, highlighting distinct signaling pathways downstream of 5-HT_2A that separate therapeutic effects from hallucinogenic side-effects.
  • Key steps completed toward an IND (Investigational New Drug) submission include FDA feedback allowing for a streamlined IND process, successful dose range finding studies, and significant manufacturing advances in CMC (chemistry, manufacturing, and controls).
  • Enveric is finalizing IND-supporting studies with the goal of initiating a first-in-human Phase 1 clinical trial in 2026—a potentially major value inflection point for shareholders.
• Pipeline Expansion and Discovery
  • Additional neuroplastogen candidates identified with the potential to promote brain-derived neurotrophic factor (BDNF) signaling, a key target for neurodegenerative diseases.
  • Publication of two peer-reviewed articles in ACS Chemical Biology and BioDesign Research underscoring Enveric’s novel bioproduction methods for neuropsychiatric drug discovery—including new approaches for synthesizing tryptamine and MDMA analogs.

Intellectual Property (IP) and Legal Developments

• Defending and Expanding Patent Portfolio
  • Notably, the Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals (related to the bretisilocin/GM-2505 molecule, acquired by AbbVie for \$1.2 billion) was withdrawn. This legal victory highlights the breadth and value of Enveric’s IP estate.
  • Multiple new U.S. patents and notices of allowance were secured, particularly for the EVM301 and EVM401 Series of compounds. The EVM401 Series includes next-generation, non-hallucinogenic mescaline derivatives with four U.S. patents issued (two in Q4 2025 alone).
  • The continued strengthening of Enveric’s IP portfolio may provide competitive advantage and licensing opportunities, potentially supporting future valuation and share price appreciation.

Corporate and Financial Highlights

• Strategic Collaborations & Licensing
  • Two licensing agreements executed with Restoration Biologics LLC for cannabinoid-COX-2 conjugate compounds (pharmaceutical and non-pharmaceutical applications).
  • Expanded partnership with TOTEC Pharma LLC for topical cannabinoid pharmaceutical products via a trademark license.
• Corporate Relocation
  • Headquarters relocated to Cambridge, MA, positioning Enveric in the heart of the Greater Boston biotech hub for enhanced access to scientific and financial resources.
• Capital Raises and Financial Position
  • Raised \$4.9 million in Q4 2025 through a warrant inducement and at-the-market (ATM) offering; total gross proceeds for FY2025 reached \$12.2 million.
  • In Q1 2026, raised an additional \$2.95 million through a registered direct offering and another ATM raise.
  • Completed a 1-for-12 reverse stock split on October 28, 2025, to maintain NASDAQ listing compliance and enhance share price stability.
  • Cash-on-hand as of December 31, 2025: \$4.7 million.
  • Net loss attributable to stockholders in Q4 2025 was \$4.0 million (including \$0.3 million in net non-cash expense), with a basic and diluted loss per share of \$6.12. This compares to a net loss of \$3.2 million (including \$1.0 million net non-cash income) and a basic/diluted loss per share of \$58.06 in Q4 2024.

CEO Commentary and Forward Outlook

“The year 2025 was a year of important scientific progress for Enveric as we further strengthened the mechanistic rationale for our lead candidate, EB-003, a non-hallucinogenic neuroplastogen, being developed for the treatment of underserved mental health conditions,” said CEO Joseph Tucker, Ph.D.

“Our excitement around EB-003 has been further amplified by recent, independent academic research… These findings… are consistent with our strategy of designing non-hallucinogenic neuroplastogens intended to deliver therapeutic benefit without the safety, monitoring, and scalability constraints associated with psychedelic compounds.”

“In 2026, we are working towards a streamlined IND application for EB-003 in preparation of the initiation of a first-in-human Phase 1 clinical trial. With the dual mechanism of action that engages both 5-HT_2A and 5-HT_1B receptors, we are optimistic that our research has the potential to profoundly impact mental health disease where innovation has been lacking for decades.”

Key Investor Takeaways and Potential Share Price Movers

• EB-003’s advancement toward IND submission and a first-in-human trial represents a major near-term catalyst. Positive preclinical data and streamlined FDA feedback could drive significant investor interest.
• The withdrawal of the PGR petition and ongoing expansion of the patent portfolio further de-risk Enveric’s platform and support long-term value creation.
• Recent capital raises and a reverse split bolster the company’s financial position, reducing delisting risks and enabling continued R&D investment.
• Any news regarding IND acceptance, clinical trial initiation, or additional licensing deals could serve as substantial share price catalysts in the coming quarters.

About Enveric Biosciences

Enveric Biosciences (NASDAQ: ENVB) is a clinical-stage biotechnology company developing next-generation, non-hallucinogenic small-molecule neuroplastogens to address unmet needs in psychiatric and neurological disorders, leveraging a differentiated discovery platform and robust, expanding IP portfolio.

Investor Relations:

Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
[email protected]

Media Relations:

Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
[email protected]

Disclaimer: This article contains forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those anticipated. Investors should review Enveric’s filings with the SEC, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, for a discussion of risks and factors that could affect the company’s future performance. This article is for informational purposes only and does not constitute investment advice.

View Enveric Biosciences, Inc. Historical chart here